AgingResearch.NewsJoin free

Agenus

CompanyUnited StatesFounded 1994

Wikidata

Agenus develops 2 assets, the furthest approved (balstilimab in microsatellite stable metastatic colorectal cancer). Mostly antibody acting on inflammation, PDCD1 and CTLA4; based in the United States, founded in 1994.

2
Assets
Furthest stage
Approved
4
Trials
0
Signals

Pipeline

2

  • balstilimab

    Anti-PD-1 monoclonal antibody blocking immune checkpoint to enhance anti-tumour T-cell responses

    Approved, Antibody, Inflammation, PDCD1, microsatellite stable metastatic colorectal cancer, ovarian cancer (Phase 1)

  • botensilimab

    Fc-enhanced anti-CTLA-4 antibody enhancing immune responses against tumours

    Approved, Antibody, Inflammation, CTLA4, microsatellite stable metastatic colorectal cancer, ovarian cancer (Phase 1)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials9
  • Similar companies6

Intelligence